Systematic review and network meta-analysis for the 2026 update of the evidence-based clinical practice guidelines for the management with immunosuppressive therapies and biologic agents of membranous nephropathy. (PubMed, Clin Exp Nephrol) - Sep 20, 2026 - "Treatment effects differed across interventions, but the overall certainty of the evidence was limited, highlighting the need for well-designed, adequately powered randomized trials with standardized methodologies."
Clinical guideline • Journal • Retrospective data • Glomerulonephritis • Infectious Disease • Nephrology • Renal Disease
|
|
Hirokazu Okada; Hiroki Nishiwaki; Izaya Nakaya; Keisuke Onishi; Kengo Furuichi; Mai Yoshida; Masahiko Yazawa; Noriaki Kurita; Reiji Takami; Sayaka Shimizu; Shinnosuke Sugihara; Tadashi Sofue; Takehiko Kawaguchi; Takehiko Wada; Takuji Ishimoto; Yasushi Tsujimoto; Yoshitaka Miyaoka; Yuji Oe; Yuki Oba
|